Shilpa Medicare Limited · NSE:SHILPAMED
Shilpa Medicare — Q1 FY21 Earnings Presentation
31 slides from Shilpa Medicare's earnings presentation, Aug 10, 2020
Slide 1: Letter to stock exchanges on analyst presentation
Shilpa Medicare Limited Corporate & Admin Office: Innovating For IIShilpa House", # 12-6-214/A-1, Hyderabad Road, I aFFordable health care Raichur-584 135, Karnataka, India Tel: +91-8532-238704, Fax: +91-8532-238876 Email: info@vbshllpa.com, Web: www.vbshilpa.com CIN: L85110KA1987PLC008739 Dated 10t
Slide 2: Q1 FY21 Results Presentation
Biological Facility - Dharwad Q1 FY21 Results Presentation Shilpa Medicare Limited (SML)
Slide 3: Disclaimer
Disclaimer Certain statements in this document may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ mat
Slide 4: Table of Contents
Table of Contents Company Overview 4 Financial Performance 15 To insert picture of Biologicals facility Way Forward 24 Annexure 26 3
Slide 5: Company Overview
Company Overview Established presence in Active Very strong R&D Pharmaceutical background in biologics Ingredients (APIs) development, and Formulations for domestic & pathway engineering and Robust research Affordable & international characterization of biologics orientation resulting in Effective m
Slide 6: Established Business Segments
Established Business Segments Description Capacities ¾ Manufacturing API products with highly API précised Isolator Technology ¾ 9 dedicated Blocks for Oncology & 4 Blocks for Non-Oncology ¾ The facility is approved by USFDA, WHO-GMP, ¾ Multi-product capability for Oncology & Non- EUGMP, TGA, PMDA,
Slide 7: Established Business Segments
Established Business Segments Description Capacities ¾ Company is pursuing an aggressive IP strategy for Bio similar and NBE assets ¾ 2 Independent lines - single use lines (1,000L Biologicals & ¾ 6 out of the top 15 Biologic products are in Bioreactor each) for production of MABS and Biosimilars th
Slide 8: Growth Business Segments
Growth Business Segments Description Capacities ¾ Company engaged in R&D in various Dermatological Dermatological products ¾ R&D is carried out at Shilpa Medicare’s Formulations ¾ 2 Products are ready to be filed under which 1 in-house R&D Facility Product is Niche Generic and 1 Product is ¾ Exhibit
Slide 9: Strengths
R&D Competence Technology Edge SML’s Key Strengths Rich Scientific Talent Manufacturing Excellence 8
Slide 10: Biologicals Research & Development
Biologicals Research & Development Competence ¾ Pathway Engineering of cells – Novel cell lines with novel characteristics, high yield ¾ HT Biologics characterization – Potential to reduce the iterations/cost in the latter stages of development and clinic ¾ Multi-parallel Bioprocessing platforms wit
Slide 11: Technology Edge
¾ Fully automated world class biomanufacturing facility at Karnataka based on Single Use technology ¾ Low footprint leading to low COGS ¾ Flexibility to incorporate continuous processes with high density fed batch Technology processes Edge ¾ Environment discharge friendly, zero liquid ¾ Multiproduct
Slide 12: Rich Scientific Talent
Rich Scientific The NBE complements the MAbs Talent development platform in all phases of Current NBE Platform growth – Pipeline in Molecule (Biologicals) Biosimilars in AI disorders and Ophthalmology 50+ Media application Scientists Biosimilars with novel formulations and delivery technologies Nove
Slide 13: Patents Status as on June 30, 2020
Patents Status as on June 30, 2020 Patents Filings Granted Pending - API 201 35 166 - Formulation 104 11 93 - Films Topical & Transdermal 46 2 44 - Biologicals 7 2 5 - Others 22 1 21 TOTAL 380 51 329 12
Slide 14: Formulation Product Pipeline as on June 30, 2020
Formulation Product Pipeline as on June 30, 2020 Approved Patents Filings (Including Pending Tentative) US ANDA - On SML’s Name 22 13 9 - On Customer’s Name 20 12 8 TOTAL (In US) 42 25 17 - EU Filing 19 13 6 TOTAL (In US & EU) 61 38 23 13
Slide 15: Manufacturing Excellence
Manufacturing Excellence Facility Location Facility Type Dharwad Biologicals Manufacturing plant Bengaluru R & D (All segments except Biologics) Raichur Unit I API (Onco – Non Oncology) Raichur Unit II API (Onco – Non Oncology) and R & D API India Jadcherla Unit Formulations (Onco & Adjuvant Therapy
Slide 16: Financial Performance
Microbial Products Upstream Facility Financial Performance 15
Slide 17: Pandemic Covid-19 relief
Pandemic Covid-19 relief Supported COVID-19 relief measure PAN - INDIA by contributing to the PM CARES & CM's Relief Fund Mask, sanitizer and temperature reading equipment distributed to medical teams in rural areas Grocery kit distribution to under privileged families and daily wages earners Provid
Slide 18: Pandemic Covid-19 relief
Pandemic Covid-19 relief e 17
Slide 19: Abridged P&L Statement - Standalone
Abridged P&L Statement -Standalone (Rs. In Lakhs) Q-o-Q Particulars Q1 FY21 Q1 FY20 Change (%) Total Income (A+B+C+D+E) 21,927 15,800 39% Total Revenue from Operations (A+B+C+D) 21,664 15,456 40% • API (A) 14,708 11,048 33% • Formulations (B) 5,619 3,150 78% • Service Income & License Fees (C) 626 7
Slide 20: Abridged P&L Statement - Consolidated
Abridged P&L Statement - Consolidated (Rs. In Lakhs) Particulars Q1 FY21 Q1 FY20 Q-o-Q Change (%) Total Income (A+B+C) 22,835 16,297 40% • Revenue from operations (A) 21,532 15,399 40% • Service Income and License fees (B) 755 700 8% • Other Income (C) 548 198 176% Total Expenditure 15,712 13,219 19
Slide 21: Results Snapshot (Standalone)
Results Snapshot (Standalone) Revenue Breakup (In Lakhs) Key Highlights Q1FY21 Q1FY20 14,708 11,048 • Formulation revenues were higher due to an increase in the sales of products 5,619 • API revenues were higher on account of delivering a better growth in the 3,150 Oncology API business 710 700 559
Slide 22: Historical Revenue Statement – Standalone
Historical Revenue Statement – Standalone Total Revenue –13.66% CAGR in last 3 years (Rs. In Lakhs) 2018 2019 2020 2,332 1,553 2,334 2,553 1,126 3,117 3,027 8,968 3,602 8,909 38,821 16,596 34,817 19,115 36,511 Strong trends in underlying performance ex of CRAMS over the past few years 21
Slide 23: Corporate updates
Corporate updates Formulations ¾ USFDA held an audit from 13 February to 25 February at the finished Dosage Formulation Facility in Jadcherla, Form 483 issued with 15 observations, SML is working Future Growth Businesses with USFDA to address the observations in a ¾ R&D Facility at Bangalore is stat
Slide 24: Managing Director’s Message
Managing Director’s Message Commenting on Q1 FY’21 performance, Mr. Vishnukant Chaturbhuj Bhutada, Managing Director Shilpa Medicare Limited said “We are pleased to deliver a steady performance during the quarter despite of facing a volatile and challenging macro-environment. We delivered a revenue
Slide 25: Way Forward
Microbial Products Purification Suite Way Forward 24
Slide 26: Way Forward
Way Forward API Formulations Future Growth Businesses ¾ Plan to commercialize ¾ To attain economies of ¾ Diversification into other therapeutic areas like 3-4 new molecules each scale by increasing Biologics, portfolio expansion to Transdermal Dosage year batch sizes Forms and Oral thin films formul
Slide 27: Annexures
Mab Fermentation Facility Annexures 26
Slide 28: Biologicals Key Highlights
Biologicals Key Highlights : Filling facility – Fully Automated MAb purification suite – fully automated 27
Slide 29: Historical R&D Expenditure Trends
Historical R&D Expenditure Trends (Rs. In Lakhs) Particulars FY18 FY19 FY20 Total R&D Expenditure 7,813 8,751 12,883 R&D Revenue Expenditure 5,386 4,004 6,948 R&D Intangible Assets 2,427 4,747 5,935 (incl. CWIP) R&D as a % of Revenue 10% 13% 16% Strong orientation on R&D to sustain growth performanc
Slide 30: About Shilpa Medicare Ltd.
About Shilpa Medicare Ltd. Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1989 at Raichur, Karnataka- India. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.
Slide 31: Thank You
Biological Division Team Thank You